Cologuard - רווח נקי למניה בארבעת הרבעונים האחרונים EXAS

Exact Sciences generates revenue through the implementation of high-tech molecular tests Cologuard and Oncotype DX. The growth rate of net income per share YoY ttm clearly demonstrates the profitability trend, where the latest figure stands at 79.50. However, it is necessary to critically assess the dependence on clinic partnerships and the current liquidity surplus, which forms the company's essential financial reserve.

The implementation of the Exact Sciences strategy to introduce non-invasive cancer diagnostics is reflected in the year-over-year (TTM) EPS comparison. This metric measures the dynamics of net profit per share over a rolling year, excluding short-term market noise. The current value of 79.50 demonstrates the scaling efficiency of Cologuard and investments in multi-cancer tests. The steady growth of this indicator confirms the fundamental resilience of the business in the face of technological competition.